









Markets
/
Stocks
/
nasdaq-axsm
/

Axsome Therapeutics Inc

AXSM

156.350USD

-7.915-4.82%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

2.77BMarket Cap

LossP/E TTM



Axsome Therapeutics Inc

156.350

-7.915-4.82%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Axsome Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Axsome Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 223.32.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Axsome Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

33 / 157

Overall Ranking

106 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Axsome Therapeutics Inc Highlights

StrengthsRisks

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 135.96% year-on-year.

Undervalued

The company’s latest PE is -42.46, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 38.50M shares, increasing 0.21% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 170.00K shares of this stock.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

223.316

Target Price

+40.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Axsome Therapeutics Inc is 8.17, ranking 68 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 196.00M, representing a year-over-year increase of 65.03%, while its net profit experienced a year-over-year increase of 61.88%.

Score

Industry at a Glance

Previous score

8.17

Change



Financials

6.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.93

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.46

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Axsome Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Axsome Therapeutics Inc is 7.11, ranking 96 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -42.46, which is -76.01% below the recent high of -10.19 and -6.42% above the recent low of -45.19.

Score

Industry at a Glance

Previous score

7.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 33/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Axsome Therapeutics Inc is 8.60, ranking 20 out of 157 in the Pharmaceuticals industry. The average price target is 185.00, with a high of 205.00 and a low of 148.00.

Score

Industry at a Glance

Previous score

8.60

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

223.316

Target Price

+40.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Axsome Therapeutics Inc

AXSM

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Axsome Therapeutics Inc is 6.90, ranking 51 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 166.21 and the support level at 149.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.03

Change

-2.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

1.305

Neutral

RSI(14)

40.248

Neutral

STOCH(KDJ)(9,3,3)

54.377

Sell

ATR(14)

5.261

High Vlolatility

CCI(14)

-14.917

Neutral

Williams %R

75.814

Sell

TRIX(12,20)

-0.395

Sell

StochRSI(14)

20.782

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

159.597

Sell

MA10

159.105

Sell

MA20

160.494

Sell

MA50

172.981

Sell

MA100

162.354

Sell

MA200

138.482

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Axsome Therapeutics Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.28%, representing a quarter-over-quarter decrease of 2.16%. The largest institutional shareholder is The Vanguard, holding a total of 4.16M shares, representing 8.13% of shares outstanding, with 3.39% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Antecip Capital, L.L.C.

7.34M

The Vanguard Group, Inc.

Star Investors

4.17M

+5.97%

BlackRock Institutional Trust Company, N.A.

3.10M

-1.23%

T. Rowe Price Associates, Inc.

Star Investors

994.50K

+72.68%

Wellington Management Company, LLP

1.33M

+84.07%

Invesco Advisers, Inc.

949.36K

+79.62%

Deep Track Capital LP

900.00K

+12.31%

Geode Capital Management, L.L.C.

997.70K

+0.83%

Nomura Investment Management Business Trust

1.08M

-4.68%

State Street Investment Management (US)

942.96K

-1.62%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Axsome Therapeutics Inc is 7.20, ranking 42 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Axsome Therapeutics Inc’s latest ESG disclosure is at an average level in the Pharmaceuticals industry, showing no material impact on overall risk.